Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Twitter Discourse on Nicotine as Potential Prophylactic or Therapeutic for COVID-19

Ramakanth Kavuluru, Jiho Noh, Shyanika W. Rose
doi: https://doi.org/10.1101/2021.01.05.21249284
Ramakanth Kavuluru
1Division of Biomedical Informatics, Internal Medicine, 230E MDS Bldg, 725 Rose St, Lexington KY 40506
Roles: Associate Professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rvkavu2@uky.edu
Jiho Noh
2Computer Science Department, Lexington, KY
Roles: doctoral student
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shyanika W. Rose
3Center for Health Equity Transformation and Department of Behavioral Science, College of Medicine, Lexington, KY
Roles: Assistant Professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Objective The low observed prevalence of smokers among hospitalized COVID-19 patients in certain cohorts has led to a hypothesis regarding nicotine’s therapeutic role in COVID-19 prevention and treatment. As new scientific evidence surfaces, premature conclusions about nicotine are rife in social media, especially unwarranted leaps of such associations to vaping and smoking. This study reports on the prevalence of such leaps and the nature of authors who are making them.

Methods We used a Twitter API subscription service to download tweets (n = 17,533) that match terms indicating nicotine or vaping themes, in addition to those that point to a prophylactic or therapeutic effect and COVID-19 (January-July 2020). Using a windowing approach, we focused on tweets that are more likely to convey the therapeutic intent. We hand-annotated these filtered tweets and built a classifier that identifies tweets that extrapolate a nicotine link to vaping/smoking. We analyzed the frequently used terms in author bios, top Web links, and hashtags of such tweets.

Results 21% of our filtered tweets indicate a vaping/smoking-based prevention/treatment narrative. Our classifier was able to spot tweets that make unproven claims about vaping/smoking and COVID-19 with a positive predictive value of 85%. Qualitative analyses show a variety of ways therapeutic claims are being made and user bios reveal pre-existing notions of positive stances toward vaping.

Conclusion The social media landscape is a double-edged sword in tobacco communication. Although it increases information reach, consumers can also be subject to confirmation bias when exposed to inadvertent or deliberate framing of scientific discourse that may border on misinformation. This calls for circumspection and additional planning in countering such narratives as the COVID-19 pandemic continues to ravage our world.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work is primarily supported by the U.S. National Cancer Institute (NCI) through NIH grant R21CA218231. Partial support is also provided by the U.S. NCI through grant P30CA177558. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The University of Kentucky IRB has deemed that this effort does not constitute human subjects research and has provided an exemption.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The raw tweet content data cannot be shared publicly as per Twitter's policies. In the interest of privacy, we only report aggregate metrics in the manuscript. We are happy to provide all the tweet IDs collected once the paper goes through peer review.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted January 06, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Twitter Discourse on Nicotine as Potential Prophylactic or Therapeutic for COVID-19
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Twitter Discourse on Nicotine as Potential Prophylactic or Therapeutic for COVID-19
Ramakanth Kavuluru, Jiho Noh, Shyanika W. Rose
medRxiv 2021.01.05.21249284; doi: https://doi.org/10.1101/2021.01.05.21249284
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Twitter Discourse on Nicotine as Potential Prophylactic or Therapeutic for COVID-19
Ramakanth Kavuluru, Jiho Noh, Shyanika W. Rose
medRxiv 2021.01.05.21249284; doi: https://doi.org/10.1101/2021.01.05.21249284

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Informatics
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (49)
  • Cardiovascular Medicine (448)
  • Dentistry and Oral Medicine (80)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (190)
  • Epidemiology (5218)
  • Forensic Medicine (3)
  • Gastroenterology (194)
  • Genetic and Genomic Medicine (750)
  • Geriatric Medicine (77)
  • Health Economics (212)
  • Health Informatics (694)
  • Health Policy (352)
  • Health Systems and Quality Improvement (223)
  • Hematology (98)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5820)
  • Intensive Care and Critical Care Medicine (356)
  • Medical Education (102)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (758)
  • Nursing (43)
  • Nutrition (129)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (475)
  • Ophthalmology (149)
  • Orthopedics (38)
  • Otolaryngology (94)
  • Pain Medicine (39)
  • Palliative Medicine (19)
  • Pathology (139)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (854)
  • Public and Global Health (1994)
  • Radiology and Imaging (344)
  • Rehabilitation Medicine and Physical Therapy (157)
  • Respiratory Medicine (283)
  • Rheumatology (93)
  • Sexual and Reproductive Health (72)
  • Sports Medicine (75)
  • Surgery (108)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)